TABLE 4.
In vitro activities of NB2001 and reference antimicrobial agents against recent clinical isolates of gram-positive bacteria (obtained from MRL)
| Organism (no. of strains)a and antimicrobial agent | MIC (μg/ml)b
|
||
|---|---|---|---|
| Range | 50% | 90% | |
| MS S. aureus (20) | |||
| NB2001 | 0.06-0.25 | 0.12 | 0.25 |
| Vancomycin | 0.5-1 | 0.5 | 1 |
| Linezolid | 1-2 | 2 | 2 |
| Quinupristin-dalfopristin | ≤0.12-0.5 | 0.25 | 0.25 |
| Amoxicillin-clavulanate | 0.06-2 | 0.25 | 0.5 |
| Oxacillin | ≤0.06-2 | 0.12 | 0.25 |
| Ampicillin | ≤0.25-16 | 1 | 16 |
| MR S. aureus (20) | |||
| NB2001 | 0.06-1 | 0.12 | 0.5 |
| Vancomycin | 0.5-1 | 0.5 | 1 |
| Linezolid | 1-2 | 2 | 2 |
| Quinupristin-dalfopristin | 0.25-0.5 | 0.25 | 0.5 |
| Amoxicillin-clavulanate | 0.25-4 | 2 | 4 |
| Oxacillin | 4-16 | 8 | 8 |
| Ampicillin | ≤0.25->16 | 8 | >16 |
| MS S. epidermidis (15) | |||
| NB2001 | 0.015-0.12 | 0.06 | 0.06 |
| Vancomycin | 0.5-2 | 1 | 2 |
| Linezolid | 0.5-2 | 1 | 2 |
| Quinupristin-dalfopristin | ≤0.12-0.5 | ≤0.12 | 0.25 |
| Amoxicillin-clavulanate | 0.06-0.25 | 0.12 | 0.25 |
| Oxacillin | ≤0.06-0.12 | ≤0.06 | 0.12 |
| Ampicillin | ≤0.25-16 | ≤0.25 | 1 |
| MR S. epidermis (15) | |||
| NB2001 | 0.03-0.5 | 0.06 | 0.25 |
| Vancomycin | 1-2 | 1 | 2 |
| Linezolid | ≤0.25-1 | 1 | 1 |
| Quinupristin-dalfopristin | ≤0.12-0.25 | 0.12 | 0.25 |
| Amoxicillin-clavulanate | 0.25-4 | 1 | 2 |
| Oxacillin | 2->32 | 4 | 32 |
| Ampicillin | ≤0.25-8 | 2 | 8 |
| PS S. pneumoniae (4) | |||
| NB2001 | 0.12-0.25 | 0.12 | 0.25 |
| Vancomycin | 0.12-0.25 | 0.25 | 0.25 |
| Linezolid | 0.5-1 | 0.5 | 1 |
| Amoxicillin-clavulanate | ≤0.015-0.06 | ≤0.015 | 0.06 |
| Cefuroxime axetil | ≤0.12-0.5 | ≤0.12 | 0.5 |
| Ceftriaxone | ≤0.015-≤0.015 | ≤0.015 | ≤0.015 |
| Ampicillin | ≤0.25-≤0.25 | ≤0.25 | ≤0.25 |
| PR S. pneumoniae (6) | |||
| NB2001 | 1-8 | 2 | 8 |
| Vancomycin | 0.25-0.25 | 0.25 | 0.25 |
| Linezolid | 0.5-1 | 0.5 | 1 |
| Amoxicillin-clavulanate | 0.12-8 | 4 | 8 |
| Cefuroxime axetil | 1-32 | 8 | 32 |
| Ceftriaxone | 0.25-4 | 1 | 4 |
| Ampicillin | ≤0.25->16 | 4 | 16 |
| VS E. faecalis (10) | |||
| NB2001 | 4-8 | 4 | 8 |
| Vancomycin | 1-2 | 1 | 2 |
| Linezolid | 0.5-2 | 1 | 1 |
| Quinupristin-dalfopristin | 1-8 | 4 | 8 |
| Amoxicillin-clavulanate | 0.5-1 | 0.5 | 1 |
| Ampicillin | 1-2 | 1 | 2 |
| VR E. faecalis (5) | |||
| NB2001 | 2-8 | 4 | 8 |
| Vancomycin | 32->32 | 32 | >32 |
| Linezolid | 1-1 | 1 | 1 |
| Quinupristin-dalfopristin | 8->8 | >8 | >8 |
| Amoxicillin-clavulanate | 0.25-1 | 0.5 | 1 |
| Ampicillin | 0.5-2 | 1 | 2 |
a
MS, methicillin susceptible; MR, methicillin resistant; PS, penicillin susceptible; PR, penicillin resistant; VS, vancomycin susceptible; VR, vancomycin resistant; S. pneumoniae, Streptococcus pneumoniae; E. faecalis, Enterococcus faecalis.
b
MIC assays were performed at MRL.